-
Spinal biologics company inks $100M deal, aims to go public
Houston-based FibroBiologics, a regenerative medicine company developing treatments for chronic disease using fibroblast cells, signed an agreement with a private investment group that will provide the company with up to $100 million over the next three years. -
Stem cell sales skyrocket despite lacking FDA approval, study finds
The number of businesses and medical clinics advertising stem cell-based therapies has skyrocketed in the U.S. over the past five years, according to a study published in Cell Stem Cell Nov. 4. -
A new era in spinal fusion: 3 surgeons weigh in on the emergence of osteoimmunology and bone graft technology
Over the past few decades, rates of spinal fusions have steadily risen. However, pseudarthrosis rates— an indicator of unsuccessful spinal fusion — have not improved enough in the past 20 years to reduce the overall non-unions. With a growing number of spinal fusions, a constant pseudarthrosis rate means that each year there are more non-unions, many of which require revision surgery. -
Pacira Biosciences sees increased Exparel sales, total revenue in Q3
Pacira Biosciences reported an uptick in total sales and its Exparel injectable analgesic during the third quarter. -
Pacira Biosciences gets patent approval for Exparel
Pacira Biosciences reached a milestone with its patent for the Exparel injectable analgesic, the company said Nov. 2. -
Stockholders approve Bioventus' $518M acquisition of Misonix, closing date set
Stockholders approved Bioventus' planned acquisition of Misonix. -
Medtronic terminates deal to distribute Aziyo's cellular bone matrix products
Medtronic will no longer distribute Aziyo Biologics' cellular bone matrix products. -
DiscGenics CEO recognized by Goldman Sachs
Goldman Sachs listed DiscGenics CEO Flagg Flanagan as one of the 100 Most Intriguing Entrepreneurs of 2021, according to an Oct. 18 news release. -
Bone Therapeutics creates advisory board for stem-cell platform
Bone Therapeutics appointed a five-person scientific advisory board for guidance on developing induced pluripotent stem cell-derived mesenchymal stromal cell, the company said Oct. 12. -
Pacira BioSciences to acquire orthopedic therapeutics company
Pacira BioSciences signed an agreement to acquire Flexion Therapeutics, according to an Oct. 11 news release. -
LifeNet Health launches minimally invasive bone graft system
Virginia Beach, Va.-based LifeNet Health launched the ViviGen minimally invasive surgery delivery system. -
What surgeons are saying about regenerative medicine in 2021
Regenerative medicine remains a hot topic among spine and orthopedic surgeons. From stem cell treatments to bone grafts, biologic technology is growing, and many surgeons are optimistic. -
Regenerative medicine market to hit $172B+ by 2030
The regenerative medicine market is expected to hit $172.15 billion by 2030, according to market research from Next Move Strategy Consulting. -
7 key updates in biologics
Here are seven updates in orthopedic biologics in the last 90 days: -
Regenerative treatment clinic opens in Hawaii
A new clinic in Honolulu focuses on non-surgical treatments for orthopedic injuries. -
Bioventus lines up another $500M acquisition — 5 details
One month after Bioventus announced its plan to acquire spine devicemaker Misonix in a $518 million deal, the orthobiologics company is lining up a reported $500 million purchase of Israeli medtech company Cartiheal. -
OrthoRTI extends clinical hold of biologics drug
Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release. -
Stem Cell Institute of America sued, accused of falsely marketing treatments for ortho pain
The co-founders of the Stem Cell Institute of America are being sued, accused of marketing stem cell therapy to seniors by falsely claiming that it is an effective treatment for orthopedic conditions such as arthritis and joint pain. -
Bioventus to acquire spine company for $518M
Bioventus has entered an agreement to acquire Misonix for $518 million in a cash-and-stock transaction. -
Orthofix launches new allograft line for spine surgery
Implant manufacturer Orthofix has launched FiberFUSE Strip, a demineralized bone graft intended to promote bone growth after spine surgery, in the U.S.
Page 11 of 36